Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Ipsen
Woman and Man
Between 18 years
and 99 years
Ipsen
Update Il y a 4 ans
Étude SPINET : étude de phase 3 randomisée visant à comparer l’efficacité et la sécurité d’emploi du lanréotide au placebo en association aux meilleurs soins de support chez des patients ayant des tumeurs neuroendocrines du poumon typiques ou atypiques, bien différentiées, métastatiques et/ou non résécables. [essai clos aux inclusions]
Les tumeurs neuroendocrines prennent naissance dans les cellules du système neuroendocrinien qui sont dispersées dans tout le corps. Ces cellules reçoivent des signaux du système nerveux et fabriquent...
Country
France
organs
Appareil respiratoire - autres
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Ipsen Group, SCRAS Institut Henri Beaufour
Update Il y a 4 ans
A Phase II, Randomised, Double-Blind Study to Compare the Safety and Efficacy of One Treatment Cycle of Clostridium Botulinum Type A Toxin (50 Units) When Reconstituted from Either a 125 Unit or a 500 Unit Presentation for the Treatment of Glabellar Lines
The main objective is the assessment of the relative clinical safety of the two different presentations (125 U vial (referred to as Reloxin) and 500 U vial (Dysport®)) by comparison of the incidence a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Ipsen Pharma GmbH
Update Il y a 4 ans
Phase II multi-centre, randomised, open, comparative study of the safety and efficacy of transdermal testosterone (Testim®) compared to intramuscular testosterone depot for the induction of puberty in boys with hypogonadism and delayed puberty
To compare daily transcutaneous therapy with Testim® with the standard therapy with monthly (every four weeks) testosterone depot intramuscular injections with respect to efficacy and safety.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Ipsen
Update Il y a 6 ans
Étude D-FR-01072-001 : étude de phase 1-2 évaluant la sécurité, la tolérance et l’efficacité du 177lu-OPS201 chez des patients ayant des tumeurs neuroendocrines positives aux récepteurs de la somatostatine.
Les cellules neuroendocrines sont dispersées dans tout le corps. On les trouve dans la plupart des organes du corps, y compris dans le tube digestif, le pancréas, la thyroïde et les poumons. Elles reç...
Country
France
organs
Système endocrinien - autres
,
Système nerveux - autres
Specialty
Radiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Ipsen Limited
Update Il y a 4 ans
A Phase IV (post marketing), multicentre, open label, single group study to look at the clinical value of counting Circulating Tumour Cells in order to predict the clinical response in patients receiving deep injections of Somatuline Autogel into the fat layer of the skin to treat the symptoms of functioning Neuroendocrine Tumours (tumours which secrete hormones) which are located in the intestines
The principal objective in the study is to assess whether counting the number of circulating tumour cells (CTCs) in the bloodstream of patients with functioning neuroendocrine tumours (NETs) (tumours ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Ipsen
Update Il y a 6 ans
Étude RESILIENT : étude de phase 3 randomisée évaluant la sécurité, la tolérance de l’irinotécan liposomal et comparant son efficacité à celle du topotécan chez des patients ayant un cancer du poumon à petites cellules.
Le cancer du poumon à petites cellules représente 15 % des cancers du poumon diagnostiqués. Il y a deux types principaux de cancer du poumon à petites cellules : le carcinome à petites cellules et le ...
Country
France
organs
Poumon, type à petites cellules
Specialty
Chimiothérapie
Essai ouvert aux inclusions
More information
Man Max 99 years
Ipsen Pharma
Update Il y a 4 ans
Study to assess the effects of BN82451B and how it is absorbed, distributed and eliminated in the body, when it is given for 4 weeks to men suffering from Hungtington's disease
To evaluate the safety and tolerability of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in subjects with Huntington’s Disease (HD).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Ipsen
Update Il y a 6 ans
Étude MM-398-07-02-03 : étude de phase 2 randomisée visant à comparer la sécurité, la tolérance et l’efficacité de l’irinotécan nanoliposomal (nal-IRI) en association à d’autres traitements anticancéreux au nab-paclitaxel associé à la gemcitabine chez des patients ayant un adénocarcinome du pancréas métastatique non traité antérieurement.
Le cancer du pancréas prend naissance dans les cellules du pancréas, le plus souvent dans les cellules du canal pancréatique, donnant lieu à l’adénocarcinome du pancréas, qui représente 95 % des cas d...
Country
France
organs
Pancréas
Specialty
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Ipsen Pharma
Update Il y a 4 ans
Comparison of efficacy and safety of Nutropin (rhGH) associated with Increlex (rhIGF-1) vs Nutropin (rhGH) alone [COGROW]
To demonstrate a superior efficacy on height velocity (HV) of treatment with a combination of flexible rhIGF-1 dose and 0.035 mg/kg/day of rhGH, as compared to treatment with 0.035 mg/kg/day of rhGH o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Beaufour Ipsen Pharma
Update Il y a 4 ans
FOLLOW-UP OF THE PHASE III, MULTICENTRE, NON COMPARATIVE, ONE SINGLE GROUP, OPEN STUDY TO ASSESS THE LONG-TERM EFFICACY AND TOLERABILITY OF PAMOATE OF TRIPTORELIN 11.25 MG IN CHILDREN WITH PRECOCIOUS PUBERTY
To assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of the study.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
Next